AMGEN EPO PATENT DECISION HAS LED TO BIOTECH PATENT FILINGS WITHOUT CELL LINE INFO: SECRECY COULD UNDERMINE FURTHER ADVANCES, G-I ARGUES TO SUPREME COURT